Reviews
Description
Tom Abate's reporting on biotechnology has always been ahead of the times. The Biotech Investor tackles the brave new world of stem cells, genomics, and clones and comes up a winner. --Thom Calandra, editor in chief, CBS MarketWatch
In The Biotech Investor, San Francisco Chronicle biotechnology reporter Tom Abate explains the science, finances, time horizon, and technological and commercial potential of this burgeoning industry.EXTRA 10 % discount with code: EXTRA
The promotion ends in 17d.19:20:39
The discount code is valid when purchasing from 10 €. Discounts do not stack.
Tom Abate's reporting on biotechnology has always been ahead of the times. The Biotech Investor tackles the brave new world of stem cells, genomics, and clones and comes up a winner. --Thom Calandra, editor in chief, CBS MarketWatch
In The Biotech Investor, San Francisco Chronicle biotechnology reporter Tom Abate explains the science, finances, time horizon, and technological and commercial potential of this burgeoning industry.
Reviews